MERCK KGAA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172 EUR | +0.58% |
|
+2.84% | +20.33% |
| 07/06 | Health Care Up as Defensive Rotation Continues - Health Care Roundup | DJ |
| 06/06 | Merck KGaA Completes EUR180 Million German Distribution Center Expansion | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 3.78 times its current sales, is high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +20.33% | 8.05TCr | - | ||
| +14.11% | 914.74Cr | A- | ||
| -14.14% | 489.88Cr | A- | ||
| +43.39% | 449.46Cr | - | ||
| +18.90% | 443.95Cr | B- | ||
| +7.93% | 218.92Cr | B | ||
| -28.40% | 213.15Cr | C- | ||
| +15.93% | 210.06Cr | - | - | |
| -43.17% | 177.81Cr | - | ||
| -0.50% | 164.41Cr | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MRK Stock
- MRCK Stock
- Ratings Merck KGaA
